MET MetLife Inc.

MET LOSS NOTICE: Rosen Law Firm Reminds MetLife, Inc. Investors of Important Deadline in First Filed Case

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MetLife, Inc. (NYSE:MET) between February 27, 2013 and January 29, 2018, both dates inclusive (“Class Period”) of the April 6, 2018 lead plaintiff deadline in the first filed class action commenced by the Rosen Law Firm. The lawsuit seeks to recover damages for MetLife investors under the federal securities laws.

To join the MetLife class action, go to http://www.rosenlegal.com/cases-1279.html or call Phillip Kim, Esq. or Daniel Sadeh, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) MetLife’s practices and procedures used to estimate its reserves set aside for annuity and pension payments were inadequate; (2) MetLife had inadequate internal controls over financial reporting; and (3) as a result, defendants’ statements about MetLife’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1279.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Daniel Sadeh of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

EN
09/02/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MetLife Inc.

Moody's Ratings rates MetLife’s subordinated debentures Baa1 (hyb)

Please see for any updates on changes to the lead rating analyst and to the Moody's legal entity that has issued the rating. Please see the issuer/deal page on for additional regulatory disclosures for each credit rating. The rating of the deben...

Moody's Ratings rates MetLife’s subordinated debentures Baa1 (hyb)

New York , February 24, 2026 – Moody's Ratings (Moody's) has assigned a Baa1 (hyb) rating to the subordinated debentures issued by MetLife, Inc. (MetLife, NYSE: MET, senior debt A3). The debentures are being issued off MetLife's multi-purpose shelf registration statement filed in May 2025 and the pr...

Moody’s Ratings assigns ratings to MetLife’s shelf (senior unsecured a...

Moody’ s Ratings assigns ratings to MetLife’ s shelf. New York, January 5, 2026– Moody’ s Ratings has assigned provisional ratings to. MetLife, Inc.’ s shelf registration filed on May 16, 2025.

Metlife Inc: 1 director

A director at Metlife Inc sold/gave away 30,684 shares at 0.000USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch